An opioid is a substance whose pharmacology is defined by engagement with the endogenous opioid receptor system — the family of four G protein-coupled receptors (mu, kappa, delta, and nociceptin/ORL1) that normally respond to the body's own opioid peptides.[1]
Membership is set by receptor target, not by chemical scaffold or by use, so the grouping spans agents that look and act very differently as long as opioid receptors are central to what they do.
The class accordingly spans a wide pharmacological range. It includes high-efficacy synthetic agonists such as fentanyl, sufentanil, and U-47700; a semi-synthetic such as ethylmorphine; the partial agonist buprenorphine; dual-mechanism analgesics such as tramadol and tapentadol; the atypical antidepressant tianeptine; the competitive antagonist naloxone; and nitrous oxide, whose primary mechanism lies elsewhere but which engages the opioid system as a secondary contributor.[2] What unites them is the receptor system they touch.
Across its agonist members the class produces a consistent core: dose-dependent analgesia, sedation, euphoria, antitussive action, and slowing of gut motility, with the experiential and therapeutic profile deepening as exposure rises.[2] Opioid agonists are central to clinical pain management, surgical anaesthesia, and the treatment of opioid use disorder, and are also used non-medically; at high exposures the same dose-axis that drives analgesia drives suppression of brainstem-mediated respiratory drive.
Pharmacology
For agonist and partial-agonist members the shared biochemical event is binding to an opioid receptor — most consequentially the mu subtype — followed by activation of inhibitory Gi/o signaling.[1] Three convergent downstream consequences are common to every receptor subtype: inhibition of adenylyl cyclase and a fall in cyclic AMP, opening of inwardly rectifying potassium channels with neuronal hyperpolarization, and inhibition of voltage-gated calcium channels with reduced presynaptic transmitter release.[3] The net effect in any circuit is reduced neuronal excitability and dampened synaptic transmission.
| Receptor target | Representative members | How it reaches the shared endpoint |
|---|---|---|
| Mu-opioid receptor full agonism | fentanyl, sufentanil, ethylmorphine, U-47700 | High-efficacy Gi/o coupling at MOR drives the full analgesia–euphoria–respiratory-depression profile[4] |
| Mu partial agonism with multi-receptor profile | buprenorphine | Partial MOR activation with high receptor affinity, kappa antagonism, and nociceptin/ORL1 agonism — producing a ceiling on respiratory depression[5] |
| Mu agonism within a dual-mechanism profile | tramadol, tapentadol, tianeptine | Direct or metabolite-mediated MOR agonism layered on monoamine reuptake inhibition or other actions[2] |
| Competitive opioid receptor antagonism | naloxone | High-affinity binding at MOR, kappa, and delta receptors without activation, displacing agonists and reversing their effects[6] |
| Secondary endogenous opioid contribution | nitrous oxide | Stimulates endogenous opioid peptide release, contributing to analgesia alongside its primary NMDA-antagonist mechanism |
The functional output of receptor activation depends entirely on the circuit engaged. Activation in ascending nociceptive pathways produces analgesia; in mesolimbic reward circuitry it produces euphoria and reinforcement; in brainstem respiratory control nuclei — particularly the preBötzinger complex — it suppresses inspiratory drive.[7]
The convergent endpoint that defines the class's acute danger is this last one: a small population of mu-receptor-bearing neurons in the preBötzinger complex and adjacent pontine respiratory areas accounts for the bulk of opioid-induced respiratory depression.[8]
The mechanistic detail therefore matters less for safety than the shared endpoint. Members differ in receptor selectivity, intrinsic efficacy, kinetics, and off-target activity — buprenorphine's slow-onset partial agonism produces a respiratory-depression ceiling that high-efficacy full agonists lack — but every agonist reaches the same brainstem locus, and their effects on breathing are additive with one another and with other CNS depressants.
Substances
The class is best illustrated by members spanning the full spread of receptor activity, from high-efficacy agonism to pure antagonism.
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| Fentanyl | Mu full agonist (synthetic phenylpiperidine) | High-potency clinical analgesic and anaesthetic; narrow therapeutic window makes it the dominant agent in modern opioid overdose deaths |
| Sufentanil | Mu full agonist (synthetic phenylpiperidine) | Closely related to fentanyl; activity also at delta and kappa receptors alongside dominant MOR agonism |
| Ethylmorphine | Mu full agonist (semi-synthetic) | Historical analgesic and antitussive; partial metabolic conversion to its parent opioid alkaloid |
| U-47700 | Mu full agonist (synthetic research chemical) | High-potency non-pharmaceutical opioid; profile and overdose risk consistent with the full-agonist group |
| Buprenorphine | Mu partial agonist; kappa antagonist; nociceptin agonist | The pharmacological outlier — slow kinetics and a ceiling on respiratory depression make it a cornerstone of opioid use disorder treatment[5] |
| Tramadol | Mu partial agonist (via metabolite) with monoamine reuptake inhibition | Dual mechanism; serotonergic activity adds an interaction risk not shared by pure opioids |
| Tapentadol | Mu agonist with norepinephrine reuptake inhibition | Both mechanisms contribute to analgesia; opioid component carries the dependence and overdose liability |
| Tianeptine | Mu and delta agonist with mood-modulating activity | Marketed historically as an antidepressant; supratherapeutic use produces classic opioid euphoria and severe dependence |
| Naloxone | Competitive opioid receptor antagonist | Produces no opioid effect on its own; reverses agonist toxicity, especially respiratory depression[6] |
| Nitrous oxide | Secondary opioid contributor | Primary mechanism is NMDA receptor antagonism; engages the opioid system through endogenous peptide release that contributes to its analgesia |
These members differ widely in receptor target, efficacy, and clinical use, but every agonist among them reaches the same brainstem endpoint, and their depressant effects on respiration add to one another.
Subjective Effects
The experiential profile of agonist members tracks a consistent trajectory along a single axis of deepening mu-opioid activation.[2]
| Exposure | Characteristic effects |
|---|---|
| Low | Analgesia, mild sedation, warmth, anxiolysis, cough suppression, miosis (pupil constriction), and slowing of gut motility; euphoria more prominent with faster-onset, higher-efficacy agents |
| Moderate–high | Deepening sedation, profound analgesia, cognitive slowing and psychomotor impairment, orthostatic hypotension, and onset of measurable hypoventilation |
| High | Severe respiratory depression with hypoventilation progressing to hypoxia, loss of consciousness and coma; risk of aspiration in the obtunded state; cardiovascular depression; death from respiratory arrest without reversal |
Because the same mu-receptor axis drives analgesia, euphoria, and respiratory depression, the margin between an analgesic or euphoric exposure and a life-threatening one narrows sharply as potency rises and as additional depressants are added.[7] Kappa-receptor activation, more prominent at high doses and in some atypical members, can overlay dysphoric, sedative, and psychotomimetic qualities onto the classical mu-mediated picture.[5]
Safety
Risk profile
The defining acute danger of this class is dose-dependent suppression of brainstem respiratory drive by mu-opioid agonists, which can progress to fatal respiratory arrest. The risk rises steeply with agonist potency, and rises again — additively or synergistically — when an opioid is combined with any other CNS depressant, including alcohol, benzodiazepines, and other sedative-hypnotics.High-potency full agonists such as fentanyl, sufentanil, and U-47700 narrow the margin between an effective and a lethal exposure to the point where small dosing errors can be fatal.
Opioid overdose is a major source of population-level mortality. Roughly 806,000 people in the United States died from opioid-related overdose between 1999 and 2023, with approximately 80,000 opioid-involved deaths in 2023 alone.[9] Polydrug use is the dominant pattern: combinations with other depressants drive much of the lethal risk, and nearly 47% of opioid overdose deaths in 2023 also involved a stimulant.[9]
Naloxone competitively displaces agonists at mu, kappa, and delta receptors and reliably reverses opioid-mediated respiratory depression when given in time.[6] Two practical limitations matter. Naloxone has no effect on respiratory depression caused by non-opioid agents such as alcohol or benzodiazepines, so in a mixed-depressant overdose it reverses only the opioid contribution. Its duration of action is also shorter than that of some high-potency opioids, particularly fentanyl, so repeat dosing and continued monitoring are often required.[6]
Tolerance & dependence
With repeated agonist exposure, tolerance develops at multiple cellular levels: receptor phosphorylation, β-arrestin recruitment, receptor internalization and desensitization, and homeostatic upregulation of adenylyl cyclase and cAMP signaling.[3] Cross-tolerance among mu agonists is the rule rather than the exception, which gives opioid rotation its clinical logic and also explains why a person tolerant to one full agonist is not protected against the additive respiratory effects of another.
Physical dependence develops alongside tolerance and can emerge even with therapeutic, medically supervised use.[4] Discontinuation produces a characteristic withdrawal syndrome featuring dysphoria and anxiety, yawning, lacrimation, rhinorrhea, diaphoresis, piloerection, myalgia, tachycardia, hypertension, nausea, vomiting, diarrhea, and insomnia, with onset and duration set by the half-life of the compound.[10]
Unlike alcohol or benzodiazepine withdrawal, uncomplicated opioid withdrawal in otherwise healthy adults is profoundly distressing but is not typically directly life-threatening.[10] The more dangerous pattern is the loss of acquired tolerance that follows a period of abstinence: returning to a previously tolerated dose after a gap carries a sharply elevated overdose risk at that same quantity, and this tolerance-naivety relapse is one of the most lethal moments in opioid dependence.
Recovery
Opioid dependence is treatable, and the pathway is well established. Medications for opioid use disorder are evidence-based and substantially reduce mortality, illicit opioid use, and overdose risk; buprenorphine is one cornerstone of this approach, alongside other agonist and antagonist options used in maintenance treatment.[11]Take-home naloxone, supervised induction onto medication treatment, and linkage to ongoing support form the framework most likely to keep someone alive through both active use and the high-risk weeks after a period of abstinence. A clinician, an addiction medicine service, or a community harm-reduction program can structure a safe entry into treatment.
Recovery resources, crisis lines, and support pathways → View all
Sub-classes
Members
references
- [1] ^abKieffer, B.L. and Evans, C.J. (2009) Opioid receptors: from binding sites to visible molecules in vivo — Neuropharmacology doi:10.1016/j.neuropharm.2008.07.033
- [2] ^abcdTrescot, A.M. and Datta, S. and Lee, M. and Hansen, H. (2008) Opioid pharmacology — Pain Physician PMID:18443637
- [3] ^abChristie, M.J. (2008) Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction — British Journal of Pharmacology doi:10.1038/bjp.2008.100
- [4] ^abKosten, T.R. and George, T.P. (2002) The Neurobiology of Opioid Dependence: Implications for Treatment — Science & Practice Perspectives doi:10.1151/spp021113
- [5] ^abcdLutz PE, Kieffer BL (2012) Opioid receptors: distinct roles in mood disorders — Trends in Neurosciences doi:10.1016/j.tins.2012.11.002
- [6]